Maryella Gifford

Statistics

Publications

Citations

H-Index

Active since

2014

Affiliations

AbbVie (United States)(Current)

Dana-Farber Cancer Institute

South Texas Accelerated Research Therapeutics

Hospital Universitario Fundación Jiménez Díaz

Maryella Gifford is an author at AbbVie (United States) specializing in oncology, antibody-drug conjugate antibodies, and therapeutic monoclonal antibodies.

Publications per year

2014–2020

Publications

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

James M. Cleary, Emiliano Calvo, Víctor Moreno et al. · Investigational New Drugs · 2020 · 31 citations

Medicine, Oncology, Pharmacokinetics +17

The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Sven de Vos, Christopher R. Flowers, Ding Wang et al. · Blood · 2014 · 15 citations

Pharmacy, Oncology, Pharmacotherapy +12

Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.

Emiliano Calvo, James M. Cleary, Víctor Moreno et al. · Journal of Clinical Oncology · 2017 · 12 citations

Pharmacy, Oncology, Pharmacology +17

1–3 of 3